Olanzapine for treatment of the schizophrenia prodrome: 2-year results of a randomized placebo-controlled study

被引：0
|
作者：
McGlashan, TH
Zipursky, RB
Perkins, DO
Addington, J
Woods, SW
Miller, TJ
Lindborg, SR
Trzaskoma, Q
Hawkins, K
Breier, A
机构：
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ N Carolina, Chapel Hill, NC 27515 USA
[4] Yale Univ, New Haven, CT 06520 USA
[5] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
BIOLOGICAL PSYCHIATRY | 2004年 / 55卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
807
引用
收藏
页码：226S / 226S
页数：1
相关论文
共 50 条
  • [1] Olanzapine for treatment of the schizophrenia prodrome: 2-year results of a randomized placebo-controlled study
    McGlashan, TH
    Zipursky, RB
    Perkins, DO
    Addington, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 164 - 164
  • [2] Olanzapine versus placebo treatment of the schizophrenia prodrome: One year results
    McGlashan, TH
    Zipursky, RB
    Perkins, DO
    Addington, J
    Woods, SW
    Miller, TJ
    Lindborg, S
    Marquez, E
    Hawkins, K
    Hoffman, RE
    Tohen, M
    Breier, A
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 295 - 295
  • [3] A 2-year placebo-controlled study of orlistat in the treatment of obesity.
    Lucas, C
    DIABETES, 1997, 46 : 339 - 339
  • [4] Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
    Hager, Klaus
    Baseman, Alan S.
    Nye, Jeffrey S.
    Brashear, H. Robert
    Han, John
    Sano, Mary
    Davis, Bonnie
    Richards, Henry M.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 391 - 401
  • [5] A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine
    Smolders, RGV
    Vogelvang, TE
    Mijatovic, V
    van Baal, WM
    Neele, SJM
    Netelenbos, JC
    Kenemans, P
    van der Mooren, MJ
    MATURITAS, 2002, 41 (02) : 105 - 114
  • [6] Results from a double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia
    Dittmann, R. W.
    Krzyhanovskaya, L.
    Schulz, C.
    McDougle, C. J.
    Frazier, J. A.
    Robertson-Plouch, C.
    Bauer, T.
    Xu, W.
    Wang, W. V.
    Carlson, J.
    Corya, S.
    Tohen, M.
    SCHIZOPHRENIA RESEARCH, 2006, 86 : S133 - S133
  • [7] Olanzapine in the treatment of schizophrenia in adolescents: An ongoing double-blind placebo-controlled study
    Joan, S
    Earley, WR
    Kryzhanovskaya, L
    Miner, C
    Dittmann, RW
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 489 - 489
  • [8] A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia
    Lieberman, Jeffrey A.
    Papadakis, Kelly
    Csernansky, John
    Litman, Robert
    Volavka, Jan
    Jia, Xinwei Daniel
    Gage, Allyson
    NEUROPSYCHOPHARMACOLOGY, 2009, 34 (05) : 1322 - 1329
  • [9] A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia
    Jeffrey A Lieberman
    Kelly Papadakis
    John Csernansky
    Robert Litman
    Jan Volavka
    Xinwei Daniel Jia
    Allyson Gage
    Neuropsychopharmacology, 2009, 34 : 1322 - 1329
  • [10] Efficacy of olanzapine in adolescents with schizophrenia: Results from a double-blind, placebo-controlled study
    Kryzhanovskaya, L.
    Dittmann, R. W.
    Robertson-Plouch, C.
    Bauer, T.
    Xu, W.
    Wang, W. V.
    Carlson, J.
    Tohen, M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S276 - S276
12345